

SENTINEL ARTICLES IN GYNECOLOGIC CANCER

Disclaimer: This list represents a collection of articles identified by members of SGO as important in the context of specific disease sites, it is not meant to serve as a specific tool of study for examinations and has not been approved by governing organizations in education

Cervix Cancer

1. Massad LS. Assessing disease extent in women with bulky or clinically evident metastatic cervical cancer: yield of pretreatment studies. *Gynecol Oncol.* 2000;76(3):383–387.
<https://pubmed.ncbi.nlm.nih.gov/10684715/>
2. Havrilesky LJ. FDG-PET for management of cervical and ovarian cancer. *Gynecol Oncol.* 2005;97(1):183–191. <https://pubmed.ncbi.nlm.nih.gov/15790456/>
3. Amit A. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. *Gynecol Oncol.* 2006;100(1):65–69. <https://pubmed.ncbi.nlm.nih.gov/16269172/>
4. Landoni F. Class II vs. class III radical hysterectomy in stage IB–IIA cervical cancer: a prospective randomized study. *Gynecol Oncol.* 2001;80(1):3–12. <https://pubmed.ncbi.nlm.nih.gov/11136561/>
5. Landoni F. Randomised study of radical surgery vs. radiotherapy for stage Ib–IIa cervical cancer. *Lancet.* 1997;350(9077):535–540. <https://pubmed.ncbi.nlm.nih.gov/9284774/>
6. Wolf JK. Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. *Obstet Gynecol.* 1996;88(1):82–86. <https://pubmed.ncbi.nlm.nih.gov/8684768/>
7. Greer BE. Stage IA2 squamous carcinoma of the cervix: difficult diagnosis and therapeutic dilemma. *Am J Obstet Gynecol.* 1990;162(6):1409–1411. <https://pubmed.ncbi.nlm.nih.gov/2360573/>
8. Sutton G. Ovarian metastasis in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1992; 166(1):50–53. <https://pubmed.ncbi.nlm.nih.gov/1733218/>
9. Whitney CW. The abandoned radical hysterectomy: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2000;79(3):350–356. <https://pubmed.ncbi.nlm.nih.gov/11104604/>

10. Cosin JA. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. *Cancer*. 1998;82(11):2241–2248. <https://pubmed.ncbi.nlm.nih.gov/9610705/>
11. Ziebarth AJ. Completed vs. aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemo-radiation therapy. *Gynecol Oncol*. 2012;126(1):69–72. <https://pubmed.ncbi.nlm.nih.gov/22484400/>
12. Potter ME. Early invasive cervical cancer with pelvic lymph node involvement: to complete or not to complete radical hysterectomy? *Gynecol Oncol*. 1990;37(1):78–81. <https://pubmed.ncbi.nlm.nih.gov/2323617/>
13. Magrina JF. The prognostic significance of pelvic and aortic lymph node metastasis. *CME J Gynecol Oncol*. 2001;6(3):302–306. <https://www.scopus.com/record/display.uri?eid=2-s2.0-0035679672&origin=inward&txGid=c0db92089dc2c96c5404b10c6a86b220>
14. Goff BA. Impact of surgical staging in women with locally advanced cervical cancer. *Gynecol Oncol*. 1999;74(3):436–442. <https://pubmed.ncbi.nlm.nih.gov/10479506/>
15. Smith KB. Postoperative radiotherapy for cervix cancer incidentally discovered after a simple hysterectomy for either benign conditions or noninvasive pathology. *Am J Clin Oncol*. 2010;33(3):229–232. <https://pubmed.ncbi.nlm.nih.gov/19806037/>
16. Rose PG. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2010;117(2):270–275. <https://pubmed.ncbi.nlm.nih.gov/20181381/>
17. Piver MS. Five classes of extended hysterectomy for women with cervical cancer. *Obstet Gynecol*. 1974;44:265–272. <https://pubmed.ncbi.nlm.nih.gov/4417035/>
18. Boran N. Scalene lymph node dissection in locally advanced cervical carcinoma: is it reasonable or unnecessary? *Tumori*. 2003;89(2):173–175. <https://pubmed.ncbi.nlm.nih.gov/12841666/>
19. Chambers SK. Sequelae of lateral ovarian transposition in irradiated cervical cancer patients. *Int J Radiat Oncol Biol Phys*. 1991;20(6):1305–1308. <https://pubmed.ncbi.nlm.nih.gov/2045304/>

20. Sedlis A. A randomized trial of pelvic radiation therapy vs. no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1999;73(2):177–183.
<https://pubmed.ncbi.nlm.nih.gov/10329031/>
21. Delgado G. Prospective surgical-pathological study of disease free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1990;38(3):352–357. <https://pubmed.ncbi.nlm.nih.gov/2227547/>
22. Peters WA. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol.* 2000;18(8):1606–1613. <https://pubmed.ncbi.nlm.nih.gov/10764420/>
23. Obermair A. Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: effect on progression-free survival. *Int J Gynecol Cancer.* 2003;13(5):633–639.
<https://pubmed.ncbi.nlm.nih.gov/14675347/>
24. Thomas G. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs. above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. *Gynecol Oncol.* 2008;108(2):317–325.
<https://pubmed.ncbi.nlm.nih.gov/18037478/>
25. Long HJ III. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. *J Clin Oncol.* 2005;23(21):4626–4633.
<https://pubmed.ncbi.nlm.nih.gov/15911865/>
26. Russell AH. Radical reirradiation for recurrent or second primary carcinoma of the female reproductive tract. *Gynecol Oncol.* 1987;27(2):226–232. <https://pubmed.ncbi.nlm.nih.gov/3570061/>
27. Monk BJ. Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery. *Gynecol Oncol.* 1994;52(2):222–228.
<https://pubmed.ncbi.nlm.nih.gov/8314143/>

28. Delgado D. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol*. 1989;35(3):314–320.
<https://pubmed.ncbi.nlm.nih.gov/2599466/>
29. Keys HM. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. *Gynecol Oncol*. 2003;89(3):343–353. <https://pubmed.ncbi.nlm.nih.gov/12798694/>
30. Rotman M. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: a follow-up of a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys*. 2006;65(1):169–176. <https://pubmed.ncbi.nlm.nih.gov/16427212/>
31. Keys HM. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med*. 1999;340(15):1154–1161.
<https://pubmed.ncbi.nlm.nih.gov/10202166/>
32. Whitney CW. Randomized comparison of fluorouracil plus cisplatin vs. hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol*. 1999;17(5):1339–1348. <https://pubmed.ncbi.nlm.nih.gov/10334517/>
33. Rose PG. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med*. 1999;340(15):1144–1153. <https://pubmed.ncbi.nlm.nih.gov/10202165/>
34. Monk BJ, Wang J, Im S. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. *Gynecol Oncol*. 2005;96(3):721–728.
<https://pubmed.ncbi.nlm.nih.gov/15721417/>
35. Varia MA. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys*. 1998;42(5):1015–1023. <https://pubmed.ncbi.nlm.nih.gov/9869224/>

36. Lanciano R. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group study. *J Clin Oncol.* 2005;23(33):8289–8295. <https://pubmed.ncbi.nlm.nih.gov/16230678/>
37. Rotman M. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. *JAMA.* 1995;274(5):387–393. <https://pubmed.ncbi.nlm.nih.gov/7616634/>
38. Morris M. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation in high-risk cervical cancer. *N Engl J Med.* 1999;340(15):1137–1143. <https://pubmed.ncbi.nlm.nih.gov/10202164/>
39. Eifel PJ. Pelvic irradiation with concurrent chemotherapy vs. pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. *J Clin Oncol.* 2004;22(5):872–880. <https://pubmed.ncbi.nlm.nih.gov/14990643/>
40. Pearcey R. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. *J Clin Oncol.* 2002;20(4):966–972. <https://pubmed.ncbi.nlm.nih.gov/11844818/>
41. Moore DH. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *J Clin Oncol.* 2004;22(15):3113–3119. <https://pubmed.ncbi.nlm.nih.gov/15284262/>
42. Monk BJ. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 2009;27(28):4649–4655. <https://pubmed.ncbi.nlm.nih.gov/19720909/>
43. Duenas-Gonzales A. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin vs. concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. *J Clin Oncol.* 2011;29(13):1678–1685. <https://pubmed.ncbi.nlm.nih.gov/21444871/>

44. Bentivegna, E., Gouy, S., Maulard, A., Chargari, C., Leary, A., & Morice, P. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. *Lancet Oncol* 2016, 17(6), e240-e253. <https://pubmed.ncbi.nlm.nih.gov/27299280/>
45. Lécuru, F., Mathevet, P., Querleu, D., Leblanc, E., Morice, P., Daraï, E., ... Dargent, D. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. *J Clin Oncol* 2011, 29(13), 1686-1691. <https://pubmed.ncbi.nlm.nih.gov/21444878/>
46. Cibula, D., Abu Rustum, N. R., Benedetti Panici, P., Köhler, C., Raspagliesi, F., Querleu, D., & Morrow, C. P. New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. *Gynecol Oncol* 2011, 122(2), 264-268. <https://pubmed.ncbi.nlm.nih.gov/21592548/>
47. Leath, C. A., Straughn, J. M. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. *Gynecol Oncol* 2013, 129(1), 251-257. <https://pubmed.ncbi.nlm.nih.gov/23280089/>
48. Kadkhodayan, S., Hasanzadeh, M., Treglia, G., Azad, A., Yousefi, Z., Zarifmahmoudi, L., & Sadeghi, R.. Sentinel node biopsy for lymph nodal staging of uterine cervix cancer: a systematic review and meta-analysis of the pertinent literature. *European J Surg Oncol* 2015, 41(1), 1-20. <https://pubmed.ncbi.nlm.nih.gov/25454828/>
49. Gouy, S., Morice, P., Narducci, F., Uzan, C., Martinez, A., Rey, A., ... Leblanc, E.. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. *J Clin Oncol* 2013, 31(24), 3026-3033. <https://pubmed.ncbi.nlm.nih.gov/23857967/>
50. Ramirez, P. T., Frumovitz, M., Pareja, R., Lopez, A., Vieira, M., Ribeiro, R., ... Obermair, A. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. *N Engl J Med* 2018, 379(20), 1895-1904. <https://pubmed.ncbi.nlm.nih.gov/30380365/>

51. Melamed, A., Margul, D. J., Chen, L., Keating, N. L., Del Carmen, M. G., Yang, J., ... Rauh Hain, J. A.. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. *N Engl J Med* 2018, 379(20), 1905-1914. <https://pubmed.ncbi.nlm.nih.gov/30379613/>
52. Frenel, J., Le Tourneau, C., O'Neil, B., Ott, P. A., Piha Paul, S. A., Gomez Roca, C., ... Varga, A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. *J Clin Oncol* 2017, 35(36), 4035-4041. <https://pubmed.ncbi.nlm.nih.gov/29095678/>
53. Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., ... Monk, B. J. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). *Lancet* 2017, 390(10103), 1654-1663. <https://pubmed.ncbi.nlm.nih.gov/28756902/>

Ovary/Fallopian/Primary Peritoneal

1. Duska LR, Garrett L, Henretta M, et al. When “never-events” occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. *Gynecol Oncol.* 2010;116(3):374–377. <https://pubmed.ncbi.nlm.nih.gov/19922988/>
2. Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of LN metastasis in primary mucinous carcinoma of the ovary. *Obstet Gynecol.* 2010;116(2, pt. 1):269–273. <https://pubmed.ncbi.nlm.nih.gov/20664385/>
3. Powless CA, Aletti GD, Bakkum-Gamez JN, et al. Risk factors for LN metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. *Gynecol Oncol.* 2011;122(3):536–540. <https://pubmed.ncbi.nlm.nih.gov/21636114/>
4. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. *Gynecol Oncol.* 1999;72(3):278–287. <https://pubmed.ncbi.nlm.nih.gov/10053096/>

5. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. *J Natl Cancer Inst.* 2005;97(8):560–566. <https://pubmed.ncbi.nlm.nih.gov/15840878/>
6. Garcia-Soto AE, Boren T, Wingo SN, et al. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? *Am J Obstet Gynecol.* 2012;206(3):242.e1–242.e5. <https://pubmed.ncbi.nlm.nih.gov/22055337/>
7. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. *Lancet.* 2001;357(9251):176–182. <https://pubmed.ncbi.nlm.nih.gov/11213094/>
8. Van Le L. Stage IC ovarian cancer: the clinical significance of intraoperative rupture. *Obstet Gynecol.* 2009;113(1):4–5. <https://pubmed.ncbi.nlm.nih.gov/19104352/>
9. Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2005;99(1):71–79. <https://pubmed.ncbi.nlm.nih.gov/16039699/>
10. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. *Cancer.* 2006;106(9):1933–1939. <https://pubmed.ncbi.nlm.nih.gov/16572412/>
11. Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. *Obstet Gynecol.* 2012;120(3):612–618. <https://pubmed.ncbi.nlm.nih.gov/22914471/>
12. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. MRC OV05; EORTC 55955 investigators. *Lancet.* 2010;376(9747):1155–1163. <https://pubmed.ncbi.nlm.nih.gov/20888993/>
13. Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. *J Natl Cancer Inst.* 2003;95(2):125–132. <https://pubmed.ncbi.nlm.nih.gov/12529345/>

14. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. *J Natl Cancer Inst.* 2003;95(2):113–125.
<https://pubmed.ncbi.nlm.nih.gov/12529344/>
15. Baptist Trimbos, Petra Timmers, Sergio Pecorelli, Corneel Coens, Koen Ven, Maria van der Burg, and Antonio Casado. Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized Trial PMID: PMC2911043 *J Natl Cancer Inst.* 2010 July 7; 102(13): 982–987.
<https://pubmed.ncbi.nlm.nih.gov/20445161/>
16. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. *Lancet.* 1998;352(9140): 1571–1576.
<https://pubmed.ncbi.nlm.nih.gov/9843101/>
17. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet.* 2003;361(9375):2099–2106.
<https://pubmed.ncbi.nlm.nih.gov/12826431/>
18. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup (GCIg). *J Clin Oncol.* 2009;27:1419–1425. <https://pubmed.ncbi.nlm.nih.gov/19224846/>
19. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med.* 2011;365(26):2484–2496. Erratum in: *N Engl J Med.* 2012;366(3):284.
<https://pubmed.ncbi.nlm.nih.gov/22204725/>
20. Hreshchyshyn MM, Park RC, Blessing JA, et al. The role of adjuvant therapy in stage I ovarian cancer. *Am J Obstet Gynecol.* 1980;138(2):139–145. <https://pubmed.ncbi.nlm.nih.gov/6252780/>
21. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med.* 1996;334(1):1–6. <https://pubmed.ncbi.nlm.nih.gov/7494563/>

22. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. *J Natl Cancer Inst.* 2000;92(9):699–708. <https://pubmed.ncbi.nlm.nih.gov/10793106/>
23. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol.* 2000;18(1):106–115. <https://pubmed.ncbi.nlm.nih.gov/10623700/>
24. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2006;102(3):432–439. <https://pubmed.ncbi.nlm.nih.gov/16860852/>
25. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol.* 2003;21(17):3194–3200. <https://pubmed.ncbi.nlm.nih.gov/12860964/>
26. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med.* 2011;365(26):2473–2483. <https://pubmed.ncbi.nlm.nih.gov/22204724/>
27. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. *J Natl Cancer Inst.* 2004;96(22):1682–1691. <https://pubmed.ncbi.nlm.nih.gov/15547181/>
28. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol.* 1995;13(7):1589–1599. <https://pubmed.ncbi.nlm.nih.gov/7602348/>
29. Fruscio R, Garbi A, Parma G, et al. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. *J Natl Cancer Inst.* 2011;103(4):347–351. <https://pubmed.ncbi.nlm.nih.gov/21217084/>

30. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. *J Clin Oncol*. 1996;14(7):2113–2119. <https://pubmed.ncbi.nlm.nih.gov/8683244/>
31. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. *J Clin Oncol*. 1997;15(1):193–198. <https://pubmed.ncbi.nlm.nih.gov/8996142/>
32. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. *J Clin Oncol*. 1998;16(7):2426–2434. <https://pubmed.ncbi.nlm.nih.gov/9667260/>
33. Omura GA, Brady MF, Look KY, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. *J Clin Oncol*. 2003;21(15):2843–2848. <https://pubmed.ncbi.nlm.nih.gov/12807937/>
34. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. *J Clin Oncol*. 1994;12(12):2654–2666. <https://pubmed.ncbi.nlm.nih.gov/7989941/>
35. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet*. 2009;374(9698):1331–1338. <https://pubmed.ncbi.nlm.nih.gov/19767092/>
36. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. *J Clin Oncol*. 1994;12(9):1748–1753. <https://pubmed.ncbi.nlm.nih.gov/7916038/>
37. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med*. 1996;335(26):1950–1955. <https://pubmed.ncbi.nlm.nih.gov/8960474/>

38. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol*. 2001;19(4):1001–1007. <https://pubmed.ncbi.nlm.nih.gov/11181662/>
39. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med*. 2006;354(1):34–43. <https://pubmed.ncbi.nlm.nih.gov/16394300/>
40. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2006;100(1):27–32. <https://pubmed.ncbi.nlm.nih.gov/16368440/>
41. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol*. 2003;21(13):2460–2465. <https://pubmed.ncbi.nlm.nih.gov/12829663/>
42. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m²) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. *Gynecol Oncol*. 2009;114(2):195–198. <https://pubmed.ncbi.nlm.nih.gov/19447479/>
43. McMeekin DS, Tillmanns T, Chaudry T, et al. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. *Gynecol Oncol*. 2004;95(1):157–164. <https://pubmed.ncbi.nlm.nih.gov/15385126/>
44. Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel 3 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2011;122(1):89–94. <https://pubmed.ncbi.nlm.nih.gov/21529904/>

45. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol*. 2006;24(29):4699–4707.
<https://pubmed.ncbi.nlm.nih.gov/16966687/>
46. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. *Gynecol Oncol*. 2004;95(1):1–8.
<https://pubmed.ncbi.nlm.nih.gov/15385103/>
47. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol*. 2012;30(17):2039–2045. <https://pubmed.ncbi.nlm.nih.gov/22529265/>
48. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol*. 2010;28(20):3323–3329.
<https://pubmed.ncbi.nlm.nih.gov/20498395/>
49. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. *Ann Surg Oncol*. 2006;13(12):1702–1710. <https://pubmed.ncbi.nlm.nih.gov/17009163/>
50. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. *Int J Gynecol Cancer*. 2011;21(2):289–295. <https://pubmed.ncbi.nlm.nih.gov/21270612/>
51. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. *N Engl J Med*. 1995;332(10):629–634. <https://pubmed.ncbi.nlm.nih.gov/7845426/>

52. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. *N Engl J Med.* 2004;351(24):2489–2497. <https://pubmed.ncbi.nlm.nih.gov/15590951/>
53. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med.* 2010;363(10):943–953. <https://pubmed.ncbi.nlm.nih.gov/20818904/>
54. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *J Clin Oncol.* 2002;20(5):1248–1259. <https://pubmed.ncbi.nlm.nih.gov/11870167/>
55. Hamilton CA, Miller A, Miller C, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2011;122(3):521–526. <https://pubmed.ncbi.nlm.nih.gov/21683993/>
56. Winter WE III, Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. *Obstet Gynecol.* 2002;100:671–676. <https://pubmed.ncbi.nlm.nih.gov/12383532/>
57. Gershenson DM, Silva EG, Tortolero-Luna G, et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants. *Cancer.* 1998;83(10):2157–2163. <https://pubmed.ncbi.nlm.nih.gov/9827720/>
58. Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. *Obstet Gynecol.* 2002;99(1):3–10. <https://pubmed.ncbi.nlm.nih.gov/11777502/>
59. Stewart SL, Wike JM, Foster SL, et al. The incidence of primary fallopian tube cancer in the United States. *Gynecol Oncol.* 2007;107(3):392–397. <https://pubmed.ncbi.nlm.nih.gov/17961642/>
60. Hu CY, Taymour ML, Hertig AT. Primary carcinoma of the fallopian tube. *Am J Obstet Gynaecol* 1950; 59:58–67. <https://pubmed.ncbi.nlm.nih.gov/15399626/>
61. Sedlis A. Carcinoma of the fallopian tube. *Surg Clin North Am* 1978; 58:121–129. <https://pubmed.ncbi.nlm.nih.gov/644422/>
62. Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group study (a final report). *Cancer.* 1985;56(2):243–248. <https://pubmed.ncbi.nlm.nih.gov/2988740/>

63. Williams SD, Blessing JA, Moore DH. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors: a trial of the Gynecologic Oncology Group. *Ann Intern Med.* 1989;111(1):22–27. <https://pubmed.ncbi.nlm.nih.gov/2472080/>
64. Li J, Yang W, Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. *Gynecol Oncol.* 2007;105(3):769–775. <https://pubmed.ncbi.nlm.nih.gov/17459461/>
65. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. *J Clin Oncol.* 1994;12(4):701–706. <https://pubmed.ncbi.nlm.nih.gov/7512129/>
66. Williams SD, Blessing JA, Hatch KD, et al. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. *J Clin Oncol.* 1991;9(11):1950–1955. <https://pubmed.ncbi.nlm.nih.gov/1719142/>
67. Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. *Gynecol Oncol.* 2004;95(3):496–499. <https://pubmed.ncbi.nlm.nih.gov/15581952/>
68. Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? *Gynecol Oncol.* 2009;113(1):86–90. <https://pubmed.ncbi.nlm.nih.gov/19162310/>
69. Wolf JK, Mullen J, Eifel PJ, Burke TW, Levenback C, Gershenson DM. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. *Gynecol Oncol* 1999;73(1):35–41. <https://pubmed.ncbi.nlm.nih.gov/10094877/>
70. Homesley HD, Bundy BN, Hurteau JA, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1999;72(2):131–137. <https://pubmed.ncbi.nlm.nih.gov/10021290/>
71. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. *Gynecol Oncol.* 2011;123(3):610–614. <https://pubmed.ncbi.nlm.nih.gov/21982047/>

72. Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade Lauraine, E., De Placido, S., ... Perrone, F. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol* 2014, 15(4), 396-405. <https://pubmed.ncbi.nlm.nih.gov/24582486/>
73. Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., ... Matulonis, U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012, 366(15), 1382-1392. <https://pubmed.ncbi.nlm.nih.gov/22452356/>
74. Boulanger, J., Boursiquot, J. N., Cournoyer, G., Lemieux, J., Masse, M. S., Almanric, K., & Guay, M. P. (2014). Management of hypersensitivity to platinum- and taxane-based chemotherapy: ceppo review and clinical recommendations. *Curr Oncol* 2014, 21(4), e630-e641. <https://pubmed.ncbi.nlm.nih.gov/25089112/>
75. Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., ... Swart, A. M. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. *Lancet* 2010, 376(9747), 1155-1163. <https://pubmed.ncbi.nlm.nih.gov/20888993/>
76. Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., ... Mannel, R. S. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017, 18(6), 779-791. <https://pubmed.ncbi.nlm.nih.gov/28438473/>
77. Moore, K., Colombo, N., Scambia, G., Kim, B., Oaknin, A., Friedlander, M., ... DiSilvestro, P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2018, 379(26), 2495-2505. [SOLO1 trial] <https://pubmed.ncbi.nlm.nih.gov/30345884/>
78. H. W. R., Hermans, R. H. M., ... Sonke, G. S. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. *N Engl J Med* 2018, 378(3), 230-240. <https://pubmed.ncbi.nlm.nih.gov/29342393/>
79. González Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., ... Monk, B. J. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2019, 381(25), 2391-2402. [PRIMA trial] <https://pubmed.ncbi.nlm.nih.gov/31562799/>

80. Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., ... Bookman, M. A. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. *N Engl J Med* 2019, 381(25), 2403-2415. [VELIA trial]
<https://pubmed.ncbi.nlm.nih.gov/31562800/>
81. Ray Coquard, I., Pautier, P., Pignata, S., Pérol, D., González Martín, A., Berger, R., ... Harter, P. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med* 2019, 381(25), 2416-2428. [PAOLA trial] <https://pubmed.ncbi.nlm.nih.gov/31851799/>

Endometrial Cancer

1. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. *Cancer*. 1985;56(2):403–412.
<https://pubmed.ncbi.nlm.nih.gov/4005805/>
2. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. *Cancer*. 2006;106(4):812–819. <https://pubmed.ncbi.nlm.nih.gov/16400639/>
3. Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. *Gynecol Oncol*. 2003;90(1):181–185.
<https://pubmed.ncbi.nlm.nih.gov/12821361/>
4. Geisler JP, Geisler HE, Melton ME, et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma? *Gynecol Oncol*. 1999;74(3):465–467.
<https://pubmed.ncbi.nlm.nih.gov/10479511/>
5. Mariani A, Webb MJ, Keeney GL, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? *Am J Obstet Gynecol*. 2000; 182(6):1506–1519.
<https://pubmed.ncbi.nlm.nih.gov/10871473/>
6. Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. *Gynecol Oncol*. 1990;38(1):46–48. <https://pubmed.ncbi.nlm.nih.gov/2354826/>

7. Doering DL, Barnhill DR, Weiser EB, et al. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma. *Obstet Gynecol*. 1989;74(6):930–933.
<https://pubmed.ncbi.nlm.nih.gov/2586959/>
8. Franchi M, Ghezzi F, Melpignano M, et al. Clinical value of intraoperative gross examination in endometrial cancer. *Gynecol Oncol*. 2000;76(3):357–361. <https://pubmed.ncbi.nlm.nih.gov/10684710/>
9. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. *J Clin Oncol*. 2005;23:3668–3675.
<https://pubmed.ncbi.nlm.nih.gov/15738538/>
10. Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. *Cancer*. 2006;107(8):1823–1830.
<https://pubmed.ncbi.nlm.nih.gov/16977653/>
11. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. *Gynecol Oncol*. 1995;56:29–33.
<https://pubmed.ncbi.nlm.nih.gov/7821843/>
12. Chan JK, Kapp DS, Cheung MK, et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. *Br J Cancer*. 2007;97(5):605–611.
<https://pubmed.ncbi.nlm.nih.gov/17667929/>
13. Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. *J Clin Oncol*. 2004;22(7):1234–1241.
<https://pubmed.ncbi.nlm.nih.gov/15051771/>
14. Nelson G, Randall M, Sutton G, et al. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. *Gynecol Oncol*. 1999;75(2):211–214.
<https://pubmed.ncbi.nlm.nih.gov/10525373/>

15. Ayhan A, Taskiran C, Celik C, et al. Surgical stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns. *Eur J Gynaecol Oncol.* 2002;23(6):553–556. <https://pubmed.ncbi.nlm.nih.gov/12556104/>
16. Walker JL, Piedmonte MR, Spirto NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP-2. *J Clin Oncol.* 2009;27(32):5331–5336. <https://pubmed.ncbi.nlm.nih.gov/19805679/>
17. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. *J Natl Cancer Inst.* 2008;100(23):1707–1716. <https://pubmed.ncbi.nlm.nih.gov/19033573/>
18. ASTEC/EN.5 Study Group; Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. *Lancet.* 2009;373(9658):137–148. <https://pubmed.ncbi.nlm.nih.gov/19070891/>
19. Kitchener H, Swart AM, Qian Q, et al; ASTEC study group. Efficacy of systemic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. *Lancet.* 2009;373(9658):125–136. <https://pubmed.ncbi.nlm.nih.gov/19070889/>
20. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1991;40(1):55–65. <https://pubmed.ncbi.nlm.nih.gov/1989916/>
21. Disaia PJ. Predicting parametrial involvement in endometrial cancer: is this the end for radical hysterectomies in stage II endometrial cancers? *Obstet Gynecol.* 2010;116(5):1016–1017. <https://pubmed.ncbi.nlm.nih.gov/20966681/>
22. Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. *Gynecol Oncol.* 1983;16(3):365–373. <https://pubmed.ncbi.nlm.nih.gov/6654180/>
23. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. *Gynecol Oncol.* 1994;54(3):264–268. <https://pubmed.ncbi.nlm.nih.gov/8088602/>

24. Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. *Gynecol Oncol*. 2001;81(1):92–99.
<https://pubmed.ncbi.nlm.nih.gov/11277657/>
25. Shih KK, Yun E, Gardner GJ, et al. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. *Gynecol Oncol*. 2011;122(3):608–611. <https://pubmed.ncbi.nlm.nih.gov/21664663/>
26. Kelly MG, O’Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. *Gynecol Oncol*. 2005;98(3):353–359. <https://pubmed.ncbi.nlm.nih.gov/16005947/>
27. Tanner EJ, Leitao MM Jr, Garg K, et al. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. *Gynecol Oncol*. 2011;123(3):548–552.
<https://pubmed.ncbi.nlm.nih.gov/21945551/>
28. Reed NS, Mangioni C, Malmström H, et al., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). *Eur J Cancer*. 2008 Apr;44(6):808-18. doi: 10.1016/j.ejca.2008.01.019. Epub 2008 Apr 2. Erratum in: *Eur J Cancer*. 2008 Jul;44(11):1612. PMID: 18378136.
<https://pubmed.ncbi.nlm.nih.gov/18378136/>
29. Homesley HD, Filiaci V, Markman M. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol*. 2007; 25(5):526–531. <https://pubmed.ncbi.nlm.nih.gov/17290061/>
30. Awtrey CS, Cadungog MG, Leitao MM, et al. Surgical resection of recurrent endometrial carcinoma. *Gynecol Oncol*. 2006;102(3):480–488. <https://pubmed.ncbi.nlm.nih.gov/16490236/>
31. Scudder SA, Liu PY, Wilczynski SP, et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. *Gynecol Oncol*. 2005;96(3):610–615. <https://pubmed.ncbi.nlm.nih.gov/15721401/>

32. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. *J Clin Oncol*. 1999;17(6):1736–1744. <https://pubmed.ncbi.nlm.nih.gov/10561210/>
33. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2010;116(1):15–20. <https://pubmed.ncbi.nlm.nih.gov/19840887/>
34. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol*. 2006;24:587–592. <https://pubmed.ncbi.nlm.nih.gov/16446331/>
35. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. *Obstet Gynecol*. 2010;116(5):1141–1149. <https://pubmed.ncbi.nlm.nih.gov/20966700/>
36. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. *Obstet Gynecol*. 1980;56(4):419–427. <https://pubmed.ncbi.nlm.nih.gov/6999399/>
37. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Postoperative Radiation Therapy in Endometrial Carcinoma. *Lancet*. 2000;355(9213):1404–1411. <https://pubmed.ncbi.nlm.nih.gov/10791524/>
38. Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. *Int J Radiat Oncol Biol Phys*. 2011;81(4):e631–e638. <https://pubmed.ncbi.nlm.nih.gov/21640520/>
39. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2004;92(3):744–751. <https://pubmed.ncbi.nlm.nih.gov/14984936/>

40. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet*. 2010;375(9717):816–823.
<https://pubmed.ncbi.nlm.nih.gov/20206777/>
41. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. *Gynecol Oncol*. 2008;108(1):226–233.
<https://pubmed.ncbi.nlm.nih.gov/17996926/>
42. Todo Y, Kato H, Kaneuchi M et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. *Lancet*. 2010;375(9721):1165–1172.
<https://pubmed.ncbi.nlm.nih.gov/20188410/>
43. Cohen CJ, Bruckner HW, Deppe G, et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Obstet Gynecol*. 1984;63(5):719–726.
<https://pubmed.ncbi.nlm.nih.gov/6371627/>
44. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 1994;12(7):1408–1414.
<https://pubmed.ncbi.nlm.nih.gov/8021731/>
45. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. *Gynecol Oncol*. 2006;100(2):349–354. <https://pubmed.ncbi.nlm.nih.gov/16213007/>
46. Sutton G, Axelrod JH, Bundy BN, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2005;97:755–763. <https://pubmed.ncbi.nlm.nih.gov/15913742/>
47. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2004;22(19):3902–3908. <https://pubmed.ncbi.nlm.nih.gov/15459211/>

48. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2006;24(1):36–44. <https://pubmed.ncbi.nlm.nih.gov/16330675/>
49. Gallion HH, Brunetto VL, Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2003;21(20):3808–3813. <https://pubmed.ncbi.nlm.nih.gov/14551299/>
50. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin 1 cisplatin versus doxorubicin 1 24-h paclitaxel 1 filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. *Ann Oncol*. 2004;15(8):1173–1178. <https://pubmed.ncbi.nlm.nih.gov/15277255/>
51. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*. 2004;22(11):2159–2166. <https://pubmed.ncbi.nlm.nih.gov/15169803/>
52. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2009;112:543–552. <https://pubmed.ncbi.nlm.nih.gov/19108877/>
53. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecology Oncology Group study. *Gynecol Oncol*. 2012;125:771–773. [https://www.gynecologiconcology-online.net/article/S0090-8258\(12\)00228-4/pdf](https://www.gynecologiconcology-online.net/article/S0090-8258(12)00228-4/pdf)
54. Mundt AJ, McBride R, Rotmensch J, et al. Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys*. 2001;50(5):1145–1153. <https://pubmed.ncbi.nlm.nih.gov/11483323/>

55. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2003;88(3):277–281. <https://pubmed.ncbi.nlm.nih.gov/12648575/>
56. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2007;106(1):16–22. <https://pubmed.ncbi.nlm.nih.gov/17574073/>
57. Nout, R. A., Smit, V. T., Putter, H., Jürgenliemk Schulz, I. M., Jobsen, J. J., Lutgens, L. C., ... Creutzberg, C. L. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet* 2010, 375(9717), 816-823. <https://pubmed.ncbi.nlm.nih.gov/20206777/>
58. Small, W., Beriwal, S., Demanes, D. J., Dusenbery, K. E., Eifel, P., Erickson, B., ... Gaffney, D. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. *Brachytherapy* 2012, 11(1), 58-67. <https://pubmed.ncbi.nlm.nih.gov/22265439/>
59. Kandoth, C., Schultz, N., Cherniack, A. D., Akbani, R., Liu, Y., Shen, H., ... Levine, D. A. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013, 497(7447), 67-73. <https://pubmed.ncbi.nlm.nih.gov/23636398/>
60. Slomovitz, B. M., Jiang, Y., Yates, M. S., Soliman, P. T., Johnston, T., Nowakowski, M., ... Coleman, R. L. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. *J Clin Oncol* 2015, 33(8), 930-936. <https://pubmed.ncbi.nlm.nih.gov/25624430/>
61. Paley, P. J., Veljovich, D. S., Press, J. Z., Isacson, C., Pizer, E., & Shah, C. A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging. *Am J Obstet Gynecol* 2016, 215(1), 117.e1-117.e7. <https://pubmed.ncbi.nlm.nih.gov/26743505/>

62. Ott, P. A., Bang, Y., Berton Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., ... Soria, J. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. *J Clin Oncol* 2017, 35(22), 2535-2541. <https://pubmed.ncbi.nlm.nih.gov/28489510/>
63. Rossi, E. C., Kowalski, L. D., Scalici, J., Cantrell, L., Schuler, K., Hanna, R. K., ... Boggess, J. F. (2017). A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. *Lancet Oncol* 2017, 18(3), 384-392. <https://pubmed.ncbi.nlm.nih.gov/28159465/>
64. Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Santin, A. D. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. *J Clin Oncol* 2018, 36(20), 2044-2051. <https://pubmed.ncbi.nlm.nih.gov/29584549/>
65. Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orłowski R, Sachdev P, Shumaker R, Casado Herraéz A. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. *J Clin Oncol*. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. PMID: 32167863. [KEYNOTE-146/Study 111] <https://pubmed.ncbi.nlm.nih.gov/32167863/>
66. de Boer SM, Powell ME, Mileskin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: *Lancet Oncol*. 2018. Apr;19(4):e184. PMID: 29449189 [PORTEC 3] <https://pubmed.ncbi.nlm.nih.gov/29449189/>

Uterine Carcinosarcoma and Leiomyosarcoma

1. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. -cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. *Gynecol Oncol.* 2007;107(2):177–185. <https://pubmed.ncbi.nlm.nih.gov/17822748/>
2. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 2007;25(5):526–531. <https://pubmed.ncbi.nlm.nih.gov/17290061/>
3. Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastasis in leiomyosarcoma of the uterus. *Gynecol Oncol.* 2003;91(1):209–212. <https://pubmed.ncbi.nlm.nih.gov/14529683/>
4. Giuntoli RL II, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. *Gynecol Oncol.* 2003;89(3):460–469. <https://pubmed.ncbi.nlm.nih.gov/12798712/>
5. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcoma: emphasis on impact of lymphadenectomy and oophorectomy. *Cancer.* 2008;112(4):820–830. <https://pubmed.ncbi.nlm.nih.gov/18189292/>
6. Goff BA, Rice LW, Fleischhaker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. *Gynecol Oncol.* 1993;50(1):105–109. <https://pubmed.ncbi.nlm.nih.gov/8349151/>
7. O’Cearbhaill R, Hensley ML. Optimal management of uterine leiomyosarcoma. *Expert Rev Anticancer Ther.* 2010;10(2):153–169. <https://pubmed.ncbi.nlm.nih.gov/20131992/>
8. Levenback C, Rubin SC, McCormack PM, et al. Resection of pulmonary metastases from uterine sarcomas. *Gynecol Oncol.* 1992;45(2):202–205. <https://pubmed.ncbi.nlm.nih.gov/1592288/>
9. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. *Gynecol Oncol.* 2003;90(1):170–176. <https://pubmed.ncbi.nlm.nih.gov/12821359/>

10. Hensley, M. L., Ishill, N., Soslow, R., Larkin, J., Abu Rustum, N., Sabbatini, P., ... Aghajanian, C. A. (2009). Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. *Gynecologic oncology*, 112(3), 563-567.
<https://pubmed.ncbi.nlm.nih.gov/19135708/>
11. Powell, M. A., Filiaci, V. L., Rose, P. G., Mannel, R. S., Hanjani, P., Degeest, K., ... Ueland, F. R. (2010). Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. *Journal of clinical oncology*, 28(16), 2727-2731.
<https://pubmed.ncbi.nlm.nih.gov/20421537/>
12. Kanthan, R., Senger, J. (2011). Uterine carcinosarcomas (malignant mixed müllerian tumours): a review with special emphasis on the controversies in management. *Obstetrics and Gynecology International*, 2011, 470795-470795. <https://pubmed.ncbi.nlm.nih.gov/22007228/>
13. Cantrell, L. A., Havrilesky, L., Moore, D. T., O'Malley, D., Liotta, M., Secord, A. A., ... Gehrig, P. A. (2012). A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. *Gynecologic oncology*, 127(1), 22-26. <https://pubmed.ncbi.nlm.nih.gov/22727985/>
14. George, S., Feng, Y., Manola, J., Nucci, M. R., Butrynski, J. E., Morgan, J. A., ... Krasner, C. (2014). Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. *Cancer*, 120(5), 738-743.
<https://pubmed.ncbi.nlm.nih.gov/24222211/>
15. Hensley, M. L., Patel, S. R., von Mehren, M., Ganjoo, K., Jones, R. L., Staddon, A., ... Demetri, G. D. (2017). Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. *Gynecologic oncology*, 146(3), 531-537.
<https://pubmed.ncbi.nlm.nih.gov/28651804/>

16. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. *Lancet Oncol*. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4. PMID: 28882536 [GeDDiS trial] <https://pubmed.ncbi.nlm.nih.gov/28882536/>

Vulvar Cancer

1. Modesitt SC, Waters AB, Walton L, et al. Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. *Obstet Gynecol*. 1998;92(6):962–966.
<https://pubmed.ncbi.nlm.nih.gov/9840558/>
2. Iversen T, Aalders JG, Christensen A, et al. Squamous cell carcinoma of the vulva: a review of 424 patients, 1956–1974. *Gynecol Oncol*. 1980;9(3):271–279. <https://pubmed.ncbi.nlm.nih.gov/7380345/>
3. Gonzalez Bosquet J, Kinney WK, Russell AH, et al. Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva. *Int J Radiat Oncol Biol Phys*. 2003;57(2):419–424.
<https://pubmed.ncbi.nlm.nih.gov/12957253/>
4. Stehman FB, Bundy BN, Dvoretzky PM, et al. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. *Obstet Gynecol*. 1992;79(4):490–497.
<https://pubmed.ncbi.nlm.nih.gov/1553164/>
5. de Hullu JA, van der Zee AG. Surgery and radiotherapy in vulvar cancer. *Crit Rev Oncol Hematol*. 2006;60(1):38–58. <https://pubmed.ncbi.nlm.nih.gov/16829120/>
6. Gonzalez Bosquet J, Magrina JF, Magtibay PM, et al. Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva. *Gynecol Oncol*. 2007;105(3):742–746.
<https://pubmed.ncbi.nlm.nih.gov/17379281/>

7. Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. *Gynecol Oncol*. 1990;38(3):309–314.
<https://pubmed.ncbi.nlm.nih.gov/2227541/>
8. Faul CM, Mirmow D, Huang Q, et al. Adjuvant radiation for vulvar carcinoma: improved local control. *Int J Radiat Oncol Biol Phys*. 1997;38(2):381–389.
<https://pubmed.ncbi.nlm.nih.gov/9226327/>
9. Trimble EL, Lewis JL Jr, Williams LL, et al. Management of vulvar melanoma. *Gynecol Oncol*. 1992;45(3):254–258. <https://pubmed.ncbi.nlm.nih.gov/1612500/>
10. Fishman DA, Chambers SK, Schwartz PE, et al. Extramammary Paget’s disease of the vulva. *Gynecol Oncol*. 1995;56(2):266–270. <https://pubmed.ncbi.nlm.nih.gov/7896196/>
11. Homesley HD, Bundy BN, Sedlis A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). *Am J Obstet Gynecol*. 1991;164(4):997–1003; discussion 1003–1004. <https://pubmed.ncbi.nlm.nih.gov/2014852/>
12. Homesley HD, Bundy BN, Sedlis A, et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). *Gynecol Oncol*. 1993;49(3):279–283. <https://pubmed.ncbi.nlm.nih.gov/8314530/>
13. Homesley HD, Bundy BN, Sedlis A, et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. *Obstet Gynecol*. 1986;68(6):733–740.
<https://pubmed.ncbi.nlm.nih.gov/3785783/>
14. Kunos C, Simpkins F, Gibbons H, et al. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. *Obstet Gynecol*. 2009;114(3):537–546.
<https://pubmed.ncbi.nlm.nih.gov/19701032/>
15. Stehman FB, Bundy BN, Ball H, et al. Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. *Am J Obstet Gynecol*. 1996;174(4):1128–1132; discussion 1132–1133. <https://pubmed.ncbi.nlm.nih.gov/8623839/>

16. Stehman FB, Bundy BN, Thomas G, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys*. 1992;24(2):389–396.
<https://pubmed.ncbi.nlm.nih.gov/1526880/>
17. Koh WJ, Chiu M, Stelzer KJ, et al. Femoral vessel depth and the implications for groin node radiation. *Int J Radiat Oncol Biol Phys*. 1993;27(4):969–974. <https://pubmed.ncbi.nlm.nih.gov/8244831/>
18. Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. *Int J Radiat Oncol Biol Phys*. 1998;42(1):79–85. <https://pubmed.ncbi.nlm.nih.gov/9747823/>
19. Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys*. 2000;48(4):1007–1013. <https://pubmed.ncbi.nlm.nih.gov/11072157/>
20. Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2012;124(3):529–533.
<https://pubmed.ncbi.nlm.nih.gov/22079361/>
21. Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study. *J Clin Oncol*. 2012;30(31):3786–3791. [GOG 173] <https://pubmed.ncbi.nlm.nih.gov/22753905/>
22. DiSaia PJ, Creasman WT, Rich WM. An alternate approach to early cancer of the vulva. *Am J Obstet Gynecol*. 1979;133(7):825–832. <https://pubmed.ncbi.nlm.nih.gov/434024/>
23. van der Zee AG, Oonk MH, de Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. *J Clin Oncol*. 2008;26(6):884–889. [GROINSS-V-I]
<https://pubmed.ncbi.nlm.nih.gov/18281661/>
24. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*. 2011;364(26):2507–2516.
<https://pubmed.ncbi.nlm.nih.gov/21639808/>

25. Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, van Dorst EB, van der Velden J, Hermans RH, van der Putten HW, Drouin P, Runnebaum IB, Sluiter WJ, van der Zee AG. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. *Lancet Oncol*. 2010 Jul;11(7):646-52. doi: 10.1016/S1470-2045(10)70104-2. Epub 2010 May 25. PMID: 20537946. <https://pubmed.ncbi.nlm.nih.gov/20537946/>
26. Howitt, B. E., Sun, H., Roemer, M. G., Kelley, A., Chapuy, B., Aviki, E., ... Rodig, S. J. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. *JAMA Oncol* 2016, 2(4), 518-522. <https://pubmed.ncbi.nlm.nih.gov/26913631/>
27. Woelber, L., Eulenburg, C., Grimm, D., Trillsch, F., Bohlmann, I., Burandt, E., ... Prieske, K. The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node. *Ann Surg Oncol* 2016, 23(8), 2508-2514. <https://pubmed.ncbi.nlm.nih.gov/26856721/>
28. Te Grootenhuis, N. C., van der Zee, A. G., van Doorn, H. C., van der Velden, J., Vergote, I., Zanagnolo, V., ... Oonk, M. H. (2016). Sentinel nodes in vulvar cancer: Long-term follow-up of the Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. *Gynecologic oncology*, 140(1), 8-14. <https://pubmed.ncbi.nlm.nih.gov/26428940/>
29. Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M., Oaknin, A., Kerger, J., ... Moore, K. N. (2019). Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. *J Clin Oncol* 2019, 37(31), 2825-2834. <https://pubmed.ncbi.nlm.nih.gov/31487218/>

Gestational Trophoblastic Neoplasia

1. Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. *Gynecol Oncol*. 2010;116(1):3-9. <https://pubmed.ncbi.nlm.nih.gov/19822356/>

2. Cole LA, Laidler LL, Muller CY. USA hCG reference service, 10-year report. *Clin Biochem.* 2010;43(12):1013–1022. <https://pubmed.ncbi.nlm.nih.gov/20493830/>
3. Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. *Gynecol Oncol.* 2004;95(3):423–429. <https://pubmed.ncbi.nlm.nih.gov/15581942/>
4. Curry SL, Schlaerth JB, Kohorn EI, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group study). *Am J Obstet Gynecol.* 1989;160(4):805–809; discussion 809–811. <https://pubmed.ncbi.nlm.nih.gov/2540654/>
5. Homesley HD, Blessing JA, Rettenmaier M, et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. *Obstet Gynecol.* 1988;72(3 Pt. 1):413–418. <https://pubmed.ncbi.nlm.nih.gov/2457192/>
6. Homesley HD, Blessing JA, Schlaerth J, Rettenmaier M, Major FJ. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1990;39(3):305–308. <https://pubmed.ncbi.nlm.nih.gov/2175286/>
7. Lurain, J. R., Nejad, B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. *Gynecol Oncol* 2005, 97(2), 618-623. <https://pubmed.ncbi.nlm.nih.gov/15863169/>
8. Lurain, J. R., Singh, D. K., Schink, J. C. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. *J Reprod Med* 2006, 51(10), 773-776. <https://pubmed.ncbi.nlm.nih.gov/17086805/>
9. Schmid, P., Nagai, Y., Agarwal, R., Hancock, B., Savage, P. M., Sebire, N. J., Seckl, M. J. (2009). Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. *Lancet* 2009, 374(9683), 48-55. <https://pubmed.ncbi.nlm.nih.gov/19552948/>
10. Lurain, J. R., Singh, D. K., Schink, J. C. (2010). Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score ≥ 7 . *J Reprod Med* 2010, 55(5-6), 199-207. <https://pubmed.ncbi.nlm.nih.gov/20626175/>

11. Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study. *J Clin Oncol*. 2011 1;29(7):825–831. <https://pubmed.ncbi.nlm.nih.gov/21263100/>
12. Yang, J., Zong, L., Wang, J., Wan, X., Feng, F., & Xiang, Y. Epithelioid Trophoblastic Tumors: Treatments, Outcomes, and Potential Therapeutic Targets. *J Cancer* 2019, 10(1), 11-19. <https://pubmed.ncbi.nlm.nih.gov/30662520/>
13. Ghorani, E., Kaur, B., Fisher, R. A., Short, D., Joneborg, U., Carlson, J. W., ... Seckl, M. J. Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. *Lancet* 2017, 390(10110), 2343-2345. <https://pubmed.ncbi.nlm.nih.gov/29185430/>
14. Campbell, G., Thomas, T. H., Hand, L., Lee, Y. J., Taylor, S. E., & Donovan, H. S. (2019). Caring for Survivors of Gynecologic Cancer: Assessment and Management of Long-term and Late Effects. *Seminars in oncology nursing*, 35(2), 192-201. <https://pubmed.ncbi.nlm.nih.gov/30867102/>
15. Schink JC, Filiaci V, Huang HQ, et al. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. *Gynecol Oncol*. 2020;158(2):354-360. doi:10.1016/j.ygyno.2020.05.013 PMID: 32460997. [GOG275] <https://pubmed.ncbi.nlm.nih.gov/32460997/>